This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Geniom® Technology—The Benchtop Array Facility

R. Güimil^a; M. Beier^a; M. Scheffler^a; H. Rebscher^a; J. Funk^a; A. Wixmerten^a; M. Baum^a; C. Hermann^a; H. Tahedl^a; E. Moschel^a; F. Obermeier^a; I. Sommer^a; D. Büchner^a; R. Viehweger^a; J. Burgmaier^a; C. F. Stähler^a; M. Müller^a; P. F. Stähler^a
^a Febit AG, Mannheim, Germany

Online publication date: 09 August 2003

To cite this Article Güimil, R., Beier, M., Scheffler, M., Rebscher, H., Funk, J., Wixmerten, A., Baum, M., Hermann, C., Tahedl, H., Moschel, E., Obermeier, F., Sommer, I., Büchner, D., Viehweger, R., Burgmaier, J., Stähler, C. F., Müller, M. and Stähler, P. F. (2003) 'Geniom® Technology—The Benchtop Array Facility', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 1721—1723

To link to this Article: DOI: 10.1081/NCN-120023122 URL: http://dx.doi.org/10.1081/NCN-120023122

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS Vol. 22, Nos. 5–8, pp. 1721–1723, 2003

Geniom® Technology—The Benchtop Array Facility

R. Güimil,* M. Beier, M. Scheffler, H. Rebscher, J. Funk, A. Wixmerten, M. Baum, C. Hermann, H. Tahedl, E. Moschel, F. Obermeier, I. Sommer, D. Büchner, R. Viehweger, J. Burgmaier, C. F. Stähler, M. Müller, and P. F. Stähler

Febit AG, Mannheim, Germany

ABSTRACT

Febit AG develops an integrated benchtop instrument for in situ microarrays preparation, hybridization, readout and data analysis.

Key Words: Microarray; In situ synthesis; Oligonucleotide; Gene expression profiling; Genotyping; Single nucleotide polymorphism (SNP); Resequencing.

With an increasing amount of sequence data available in public databases and more than 500 ongoing sequencing projects, biological research has entered a new era. Researchers can easily access to complete genome sequences of more than hundred model organisms. This fact allows the design of an almost infinite number of complex experiments like gene expression profiling, resequencing or SNP's detection. New flexible tools are needed to ensure that these experiments can always be adapted to the rapid growing sequence information.

In contrast to the available array-technologies, febit ag has developed an integrated microarray platform that enables any researcher to design and perform his

1721

DOI: 10.1081/NCN-120023122 Copyright © 2003 by Marcel Dekker, Inc.

> Marcel Dekker, Inc. 270 Madison Avenue, New York, New York 10016

1525-7770 (Print); 1532-2335 (Online)

www.dekker.com

^{*}Correspondence: R. Güimil, Febit AG, Käfertalerstrasse 190, D-68167 Mannheim, Germany; Fax: +49 621 380 1400; E-mail: ramon.guimil@febit.de.

1722 Güimil et al.




Figure 1. Workflow using the Geniom Oner technology: a single benchtop instrument integrates the complete process of synthesis, addition of the labelled probe, hybridisation and readout.

personalized microarray experiment. The microarray synthesis as well as hybridization, readout and data analysis take place in a single benchtop instrument, placed in the user's lab. This setup gives maximum flexibility in design and realization of all types of oligonucleotide based microarrays. (Fig. 1)

The reaction carrier, the so called DNA-ProcessorTM, is a microstructure which consists of three layers (glass-silicon-glass). The oligonucleotide synthesis takes place




Figure 2. CE-analysis of a 30-mer oligonucleotide, synthesized in a DNA-Processor employing geniom technology.

simultaneously in up to eight three-dimensional channels (arrays) (Fig. 2). During the hybridization each of those channels can be addressed individually. Therefore, the system offers the possibility to perform up to eight different experiments.

In addition, the Geniom[®] system is able to synthesize oligonucleotides not only in the conventional $3' \rightarrow 5'$, but also in the reverse $5' \rightarrow 3'$ direction. This approach expandes the use of the Geniom[®] technology to experiments with enzymes that require free 3'-end.

The Geniom® system facilitates truly custom designed experiments improving quality and applicability of array experiments. The speed of probe optimization maximizes research results. Since the instrument uses the in situ synthesis of oligonucleotides, probe length may be different even within one array to consider differences in melting points and assure for best stringency.

The Geniom® system has demonstrated to be useful for a broad range of applications including gene expression profiling, genotyping of single nucleotide polymorphism (SNPs) and resequencing. This flexibility makes it an unmissable tool in any genomics laboratory.

Febit has started a broad initiative to make a wide variety of organisms available for expression profiling studies on the Geniom[®] platform. So far, complete sets for *S. cerevisiae*, *E. coli*, *P. multocida* and *S. pneumoniae* are available. Current activities focus on establishing validated probe sets for human.